A Study to Learn More About How Safe Dienogest is and How Well it Works Under Real World Conditions in Indian Women With Endometriosis
Launched by BAYER · Mar 19, 2021
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female patients in India at least 18 years of age
- • Clinical or surgical diagnosis of endometriosis: Clinical diagnosis by suggestive symptoms and positive finding in imaging study (Chocolate cyst)
- • Patients diagnosed with endometriosis associated pelvic pain who have not been previously treated with Dienogest
- • Decision to initiate treatment with Dienogest was made as per investigator's routine treatment practice
- • Signed informed consent
- Exclusion Criteria:
- • Participation in an investigational program with interventions outside of routine clinical practice
- • Contra-indications according to the local summary of product characteristics (SPC)
About Bayer
Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Multiple Locations, , India
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials